GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Carmustine - BiCNU intravenous injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

BiCNU / carmustine IV

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

A numeric stop threshold does not cancel a broader restriction

Both retrieved sources retain broad renal non-administration wording alongside a numeric discontinuation threshold. The official document also has conflicting date fields.

Before applying: Reconcile the current exact product and oncology protocol; do not manufacture a permissive renal ladder from the threshold.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

BiCNU - carmustine intravenous kit

Product / population
BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.
Renal measure
CrCl in mL/min; equation not specified

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Renal dosing, restrictions and evidence limits

Section 2.1 retains both the broad non-administration wording for compromised renal function and the CrCl below 10 mL/min discontinuation threshold. Their scopes need reconciliation; a threshold is not a complete dosing algorithm.

The retrieved document contains differing dates: highlights 11/2021, manufacturer text 10/2020, and SPL metadata effective 2023-11-21. Marketing information includes an end date. Preserve these qualifications and confirm the current exact product before using this dated snapshot.

Source revision: Highlights 11/2021; manufacturer text 10/2020; SPL effective 2023-11-21 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

BiCNU - carmustine intravenous kit

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - BiCNU

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

BiCNU - carmustine intravenous kit

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dialysis evidence: No dialysis regimen established in selected content

BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.

Renal method: CrCl in mL/min; equation not specified
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - BiCNU

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dialysis evidence: No dialysis regimen established in selected content

BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.

Renal method: CrCl in mL/min; equation not specified
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A numeric stop threshold does not cancel a broader restriction

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

within label scope and currency hold

A numeric stop threshold does not cancel a broader restriction

Both retrieved sources retain broad renal non-administration wording alongside a numeric discontinuation threshold. The official document also has conflicting date fields.

How to use this: Reconcile the current exact product and oncology protocol; do not manufacture a permissive renal ladder from the threshold.

GlobalRPh RX List - BiCNUBiCNU - carmustine intravenous kit

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeBiCNU - carmustine intravenous kitGlobalRPh RX List - BiCNU
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/bicnu-drug/

Exact product and population

BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.

RDM58-SCOPE-carmustine-bicnu-iv · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

BiCNU - carmustine intravenous kit

Open original reference

Open / share this exact local source

DailyMed / Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.

Renal method: CrCl in mL/min; equation not specified
Source date: Highlights 11/2021; manufacturer text 10/2020; SPL effective 2023-11-21
Retrieved: 2026-09-10

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Section 2.1 retains both the broad non-administration wording for compromised renal function and the CrCl below 10 mL/min discontinuation threshold. Their scopes need reconciliation; a threshold is not a complete dosing algorithm.

The retrieved document contains differing dates: highlights 11/2021, manufacturer text 10/2020, and SPL metadata effective 2023-11-21. Marketing information includes an end date. Preserve these qualifications and confirm the current exact product before using this dated snapshot.

RDM58-official-carmustine-bicnu-iv-9f0d055896-C1 · Source locator: Section 2.1; highlights; manufacturer footer; SPL metadata and marketing information

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079
Retrieved
2026-09-10
Exact label title
BiCNU - carmustine intravenous kit
DailyMed Set ID
d6cbb63c-e0b1-43ee-ad6f-408da0772079
Labeler
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Label revision
Highlights 11/2021; manufacturer text 10/2020; SPL effective 2023-11-21
SPL version
16
FDA application
NDA017422
Renal-function method
CrCl in mL/min; equation not specified
Source date/version
Highlights 11/2021; manufacturer text 10/2020; SPL effective 2023-11-21
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
2910d3df14871c3598bce70f70b7feb3cf5f39ae9a85b5d8a62f0f45fc8d064c
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - BiCNU

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.

Renal method: CrCl in mL/min; equation not specified
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Assess renal function before treatment and periodically thereafter. The selected paragraph calls for greater toxicity surveillance in compromised renal function and discontinuation when CrCl is below 10 mL/min. It also contains a broader instruction not to administer in compromised renal function.

That broader restriction is not erased by the numerical stop threshold. The source does not provide a reconciled dose-reduction ladder. Resolve the wording and exact current product with oncology/pharmacy rather than interpreting CrCl >=10 as permission to administer.

RDM58-rxlist-carmustine-bicnu-iv-f46ac428ac-C1 · Source locator: Dosage and Administration: renal monitoring paragraph

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/bicnu-drug/
Retrieved
2026-09-10
Renal-function method
CrCl in mL/min; equation not specified
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
494a8ada30a59a9e8705f1a411bff53c2efc3d129a7cbb8b8c55804b01e79925

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/bicnu-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
00dea989018df80e4dbc121d8d7087746296177cb1ef6b791707700b009e624e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report